新生血管性年龄相关性黄斑变性治疗的研究进展

Advances in Treatment of Neovascular Age-related Macular Degeneration

年龄相关性黄斑变性(AMD)是一种中心性视力不可逆性丧失的疾病。血管内皮生长因子(VEGF)是新生血管性AMD(nAMD)发病的重要因素,目前抗VEGF治疗仍是临床一线治疗方案。尽管抗VEGF治疗在一定程度上能够减缓疾病进展和视力丧失,但患者仍需要频繁玻璃体腔注射,长期治疗效果并不理想。因此,为改善疗效,针对传统抗VEGF治疗的替代方案相继出现,如新型抗VEGF药物、基因治疗、血小板衍生生长因子抑制剂、血管生成素/Tie信号通路药物、新型药物缓释系统等。随着研究的深入,相信会有更多的延长型及多靶点药物可供nAMD患者选择。

Age-related macular degeneration(AMD)is a disease in which irreversible loss of central vision occurs.Vascular endothelial growth factor(VEGF)is an important factor in the pathogenesis of neovascular AMD(nAMD),and anti-VEGF therapy is still the first-line clinical treatment.Although anti-VEGF therapy can slow disease progression and vision loss to a certain extent,the patients still need frequent intravitreal injections,and the long-term treatment results are not ideal.Therefore,in order to improve the efficacy,alternatives to traditional anti-VEGF therapy have emerged successively,such as novel anti-VEGF drugs,gene therapy,platelet derived growth factor inhibitors,angiogenin/Tie signaling pathway drugs,and novel drug sustained-release systems.With the deepening of research,it is believed that more extended-type and multi-target drugs will be available for nAMD patients.